Allen Cox
Sunday, 26 April 2015
Celladon says heart treatment fails in trial
NEW YORK (Reuters) - Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment